Martin H. Dreyling

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 326 publications

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 14, 2026

Modern Management of Mantle Cell Lymphoma.

Modern Management of Mantle Cell Lymphoma.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 07, 2026

Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.

Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.

Journal: Blood
Published: April 01, 2026

Clinical Manifestations of Primary CNS T-Cell Lymphoma: A Retrospective Study of Histopathologic, Molecular, and Neuroimaging Features.

Clinical Manifestations of Primary CNS T-Cell Lymphoma: A Retrospective Study of Histopathologic, Molecular, and Neuroimaging Features.

Journal: Neurology
Published: March 17, 2026

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

Journal: The Lancet. Haematology
Published: March 02, 2026

High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.

High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.

Journal: Lancet (London, England)
Published: February 19, 2026

Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology.

Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology.

Journal: Leukemia
Published: February 09, 2026

Clinical decision support in hematological malignancies using a case-grounded AI agent.

Clinical decision support in hematological malignancies using a case-grounded AI agent.

Journal: Nature medicine
Published: January 27, 2026

Change in COVID-19 outcomes in lymphoma patients across pandemic waves: results of the COVID-19-lymphoma registry of the Bavarian Cancer Research Center (BZKF) 2020-2022.

Change in COVID-19 outcomes in lymphoma patients across pandemic waves: results of the COVID-19-lymphoma registry of the Bavarian Cancer Research Center (BZKF) 2020-2022.

Journal: Annals of hematology
Published: January 12, 2026

Reduce bureaucracy in clinical trials now.

Reduce bureaucracy in clinical trials now.

Journal: Nature medicine
Published: January 06, 2026

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Journal: Lancet (London, England)
Published: December 23, 2025

Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.

Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.

Journal: American journal of hematology
Published: November 21, 2025
Showing 1-12 of 326

Last Updated: 09/26/2026